Nasus Pharma

Powder-based Intra-nasal Products

Health Tech & Life Sciences
Public on NYSE on Aug 2025
Public Tel Aviv-Yafo, Israel Founded 2019
Website ↗ LinkedIn
Last updated 2026-06-18
Total raised
$25.0M
Last: 2026-02
Stage
Public
Founded
2019
Headcount
6
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

Nasus Pharma is developing a number of intranasal powder products aimed at assisting patients in several acute emergency situations (such as opioid overdose and anaphylactic shock) based on its microsphere technology. Nasus's portfolio comprises a number of programs including intranasal naloxone, intranasal epinephrine, and a number of preclinical proof-of-concept programs.

Funding history · 1 round · $25.0M total

2026-02
$15.0M

Q&A

When did Nasus Pharma go public and on what exchange?
Nasus Pharma went public on the NYSE in August 2025.
What was the total amount raised in Nasus Pharma's initial public offering?
Nasus Pharma raised $10,000,000 in its initial public offering in August 2025.
What was the valuation of Nasus Pharma at the time of its IPO?
Nasus Pharma had a valuation of $75,000,000 at the time of its IPO in August 2025.
What was Nasus Pharma's most recent funding round?
Nasus Pharma completed a funding round in February 2026, raising $15,000,000.
Which companies partnered with Nasus Pharma to support the development and commercialization of its NS002 intranasal epinephrine program?
In October 2025, Nasus Pharma announced a strategic collaboration with Aptar France S.A.S. and AptarGroup, Inc. to support the clinical development and commercialization of its NS002 intranasal epinephrine product candidate.
What regulatory milestone did Nasus Pharma achieve for its NS002 intranasal epinephrine powder formulation in November 2025?
In November 2025, Nasus Pharma received a No-Objection Letter from Health Canada to initiate its planned Phase 2 clinical study of NS002, an investigational intranasal epinephrine powder formulation for anaphylaxis treatment.
When did Nasus Pharma initiate its Phase 2 clinical study for NS002 in Canada?
Nasus Pharma initiated a Phase 2 clinical study in Canada for its investigational intranasal epinephrine powder formulation, NS002, on November 18, 2025.
Who was appointed as Executive Vice President and Chief Financial Officer at Nasus Pharma in November 2025?
In November 2025, Nasus Pharma appointed Eyal Rubin as Executive Vice President and Chief Financial Officer.
What were the interim results of Nasus Pharma's Phase 2 clinical study for NS002, announced in January 2026?
In January 2026, Nasus Pharma announced positive interim results from its Phase 2 clinical study of NS002, showing faster absorption, higher peak concentrations, and greater early epinephrine exposure compared to the EpiPen® autoinjector. 91% of participants administered NS002 reached the epinephrine plasma threshold of 100 pg/ml at 5 minutes, compared to 67% with EpiPen®.
What was the purpose of the $15 million private placement closed by Nasus Pharma in February 2026?
The $15 million private placement closed by Nasus Pharma in February 2026 will support the advancement of its intranasal epinephrine product candidate, NS002, towards a pivotal study and NDA submission, and expand its pipeline of intranasal, powder-based programs.

Team · 2

Udi Gilboa
Founder · Co-founder & Chairman
LinkedIn ↗
Dr. Dalia Meggido
Founder · Co-founder
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2B2C

Highlights

1 Patents

Tags

drug-deliverynon-invasivemedical-technologiesemergency-responsepharmaceuticalstreatmentsrespiratorybiopharmaceuticalinhalationbacteriamedical-devicespublic-health
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)